State Street Corp 9 Meters Biopharma, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.64 $786,173 - $1.94 Million	-3,023,745 Reduced 78.95%	806,171 $210,000
Q1 2022 May 16, 2022	BUY	$0.52 - $1.0 $47,736 - $91,800	91,800 Added 2.46%	3,829,916 $2.3 Million
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $216,715 - $339,095	254,959 Added 7.32%	3,738,116 $3.66 Million
Q3 2021 Nov 15, 2021	BUY	$1.03 - $1.41 $521,544 - $713,959	506,354 Added 17.01%	3,483,157 $4.53 Million
Q2 2021 Aug 16, 2021	BUY	$1.04 - $1.5 $3.1 Million - $4.47 Million	2,976,803 New	2,976,803 $3.27 Million

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.